€58.70
Your prediction
Corcept Therapeutics Inc. Stock
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
Cons
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | 3.560% | 12.869% | 45.510% | -15.423% | -16.116% | 156.071% | 222.247% |
| Rockwell Medical Inc. | 0.780% | -7.857% | -10.417% | -24.650% | -4.656% | -70.139% | -91.339% |
| Pacira Pharmaceuticals | 0.000% | 5.584% | -3.704% | -7.965% | -3.704% | -42.541% | -58.065% |
| Twist Bioscience Corp | 6.120% | 19.558% | 9.698% | 112.635% | 98.205% | 311.020% | -37.557% |
Comments
News
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week
One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (NASDAQ: CORT), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday
Corcept Therapeutics (NASDAQ: CORT) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day
On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (NASDAQ:CORT), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately


